

DAFTAR PUSTAKA

- Astrid, C., Putranti, I. O., Purwanti, K. D., Kedokteran, F., Soedirman, U. J., & Psikologi, K. 2018. Perbedaan Tingkat Keparahan Psoriasis Pada Pasien Psoriasis Dengan Dan Tanpa Fokal Infeksi Difference of Psoriasis Area Severity Index Between. *Mandala of Health a Scientific Journal*, 11(2), 80–94.
- Baker, B. S., Brent, L., Valdimarsson, H., Powles, A. V., Al-Imara, L., Walker, M., & Fry, L. 1992. Is epidermal cell proliferation in psoriatic skin grafts on nude mice driven by T-cell derived cytokines?. *British Journal of Dermatology*, 126(2), 105–110.
- Bedoui, Y., Guillot, X., Sélambarom, J., Guiraud, P., Giry, C., Jaffar-Bandjee, M. C., Ralandison, S., & Gasque, P. 2019. Methotrexate an old drug with new tricks. *International Journal of Molecular Sciences*, 20(20), 1–32.
- Bozek, A., & Reich, A. 2017. The reliability of three psoriasis assessment tools: Psoriasis area and severity index, body surface area and physician global assessment. *Advances in Clinical and Experimental Medicine*, 26(5), 851–856.
- Bubna, A. K. 2015. Imiquimod-Its role in the treatment of cutaneous malignancies. *Indian Journal of Pharmacology*, 47(4), 354–359.
- Budiastuti, A. 2011. Korelasi Kadar TNF- α dan Skor *Psoriasis Area Severity Index* (PASI) pada Pasien Psoriasis. *Media Medika Indonesiana*, 45(2), 133-137.
- Budini, S. S., Cholis, M., & Rofiq, A. 2014. Kadar TNF-Alpha lesi kulit dengan derajat keparahan psoriasis vulgaris (TNF-Alpha level in skin lesion with severity scale of psoriasis vulgaris). *Berkala Ilmu Kesehatan Kulit & Kelamin*, 26(1), 22–28.
- Burg, G., Kutzner, H., Kempf, W., Feit, J., & Smoller B. R. 2019. *Atlas of Dermatopathology*. USA : Wiley Blackwell.
- Cai, Y., Fleming, C., & Yan, J. 2012. New insights of T cells in the pathogenesis of psoriasis. *Cellular and Molecular Immunology*, 9(4), 302–309.
- Conrad, C., Boyman, O., Tonel, G., Tun-Kyi, A., Laggner, U., De Fougères, A., *et al.* 2007. $\alpha 1\beta 1$ integrin is crucial for accumulation of epidermal T cells and the development of psoriasis. *Nature Medicine*, 13(7), 836–842.
- Dahlan, M. S. 2011. *Statistik untuk Kedokteran & Kesehatan: Deskriptif, Bivariat, & Multivariat*. Edisi 5. Jakarta : Salemba Medika.
- Dewi, S., Isbagio, H., Purwaningsih, E. H., Kertia, N., Setiabudy, R., & Setiati, S. 2019. A Double-blind, Randomized Controlled Trial of Ciplukan (*Physalis angulata* Linn) Extract on Skin Fibrosis, Inflammatory, Immunology, and

- Fibrosis Biomarkers in Scleroderma Patients. *Acta Medica Indonesiana*, 51(4), 303–310.
- Di Cesare, A., Di Meglio, P., & Nestle, F. O. 2009. The IL-23/Th17 axis in the immunopathogenesis of psoriasis. *Journal of Investigative Dermatology*, 129(6), 1339–1350.
- Djuanda, A., Hamzah, M., & Aisah, S. 2010. *Ilmu Penyakit Kulit dan Kelamin*. Edisi 6. Jakarta : Fakultas Kedokteran Universitas Indonesia.
- Fitri, N. L., Roro, E. S., & Lud, W. 2016. Pengaruh Ekstrak Buah Ciplukan (*Physalis angulata L.*) terhadap Kadar SGPT dan SGOT Mencit Putih Jantan (*Mus musculus*) Hiperglikemia yang Diinduksi Aloksan sebagai with Belajar Biologi. *Jurnal Pendidikan Biologi Indonesia*, 2(2), 180–187.
- Gelfand, J. M., Neimann, A. L., Shin, D. B., Wang, X., Margolis, D. J., & Troxel, A. B. 2006. Risk of Myocardial Infarction in Patients With Psoriasis. *Journal of the American Medical Association*, 296(14), 1735–1741.
- Gisondi, P., Del Giglio, M., & Girolomoni, G. 2017. Treatment approaches tomoderate to severe psoriasis. *International Journal of Molecular Sciences*, 18(11), 2427.
- Griffiths, C. E. M., Strober, B. E., van de Kerkhof, P., Ho, V., Fidelus-Gort, R., Yeilding, N., *et al.* 2010. Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis. *New England Journal of Medicine*, 362(2), 118–128.
- Gudjonsson, J. E., & Elder, J. T. 2007. Psoriasis: epidemiology. *Clinics in Dermatology*, 25(6), 535–546.
- Hadiyanti, N., Pardono., & Supriyadi. 2017. Kerapatan dan Sifat Morfologi Ciplukan (*Physalis sp.*) di Gunung Kelud, Jawa Timur. *Jurnal Hijau Cendekia*, 2(2), 71–77.
- Irianto, K. 2004. *Struktur dan Fungsi Tubuh Manusia untuk Paramedis*. Bandung : Yrama Widya.
- Jacobo-Herrera, N. J., Bremner, P., Márquez, N., Gupta, M. P., Gibbons, S., Muñoz, E., & Heinrich, M. 2006. Physalins from *Witheringia solanacea* as modulators of the NF- κ B cascade. *Journal of Natural Products*, 69(3), 328–331.
- James, W.D., Berger, T.G., & Elston, D.M. 2006. *Andrew's Diseases of the Skin Clinical Dermatology 10th edition*. Canada : Elsevier Inc.
- Ji, L., Yuan, Y., Luo, L., Chen, Z., Ma, X., Ma, Z., & Cheng, L. 2012. Physalins with anti-inflammatory activity are present in *Physalis alkekengi* var. *franchetii* and can function as Michael reaction acceptors. *Steroids*, 77(5), 441–447.
- Johnson, M. 2012. Laboratory Mice and Rats. *Mater Methods*, 2012(2), 113.

- Jyothibasu, T., & Ramana, K. V. 2015. Pharmacological review on *Physalis* species: a potential herbal cure - all. *World Journal of Pharmaceutical Research*, 4(2), 247–256.
- Keumala, W., Shafira, A., Arlha, A. D., Endi, N., Eyleny, M. F., & Evita, H. 2019. Kesesuaian Tata Laksana Psoriasis Dengan Panduan Praktik the Conformity of Psoriasis Management According To Practical Clinical Guidelines in Dr . Cipto Mangunkusumo National Central General Hospital. *Media Dermato-Venereologica Indonesiana*, 46(4), 172–177.
- Kris, M. V., Adiguna, M. S., & Wardhana, M. 2019. Sindrom metabolik merupakan faktor risiko terjadinya psoriasis. *Medicina*, 50(2), 421–424.
- Krisnarto, E., Novitasari, A., & Aulirahma, D. M. 2016. Faktor Prediktor Kualitas Hidup Pasien Psoriasis : Studi Cross Sectional. *Jurnal Unimus*, 5(1), 43–51.
- Krueger, G., & Ellis, C. N. 2005. Psoriasis - Recent advances in understanding its pathogenesis and treatment. *Journal of the American Academy of Dermatology*, 53(1), 94–100.
- Kuchekar, A. B., Pujari, R. R., Kuchekar, S. B., Dhole, S. N., & Mule, P. M. 2011. Psoriasis: comprehensive review. *International Journal of Pharmacy and Life Sciences*, 2(6), 857–877.
- Langley, R. G. B., Krueger, G. G., & Griffiths, C. E. M. 2005. Psoriasis: Epidemiology, clinical features, and quality of life. *Annals of the Rheumatic Diseases*, 64(2), 18–24.
- LaRosa, D. F., & Orange, J. S. 2008. Lymphocytes. *Journal of Allergy and Clinical Immunology*, 121(2), 364–369.
- Lew, W., Bowcock, A. M., & Krueger, J. G. 2004. Psoriasis vulgaris: Cutaneous lymphoid tissue supports T-cell activation and “Type 1” inflammatory gene expression. *Trends in Immunology*, 25(6), 295–305.
- Lim, T. K. 2013. *Edible Medicinal And Non-Medicinal Plants*. Dordrecht : Springer Science.
- Lorthoix, I., Simard, M., Morin, S., & Pouliot, R. 2019. Infiltration of T cells into a three-dimensional psoriatic skin model mimics pathological key features. *International Journal of Molecular Sciences*, 20(7), 1670.
- Lowes, M. A., Suárez-Fariñas, M., & Krueger, J. G. 2014. Immunology of psoriasis. *Annual Review of Immunology*, 32, 227–255.
- Luliana, S., Susanti, R., & Agustina, E. 2017. Antiinflammatory Activity Test of Aqueous Extracts Herb of Ciplukan (*Physalis angulata* L.) in Caragenan Induced Wistar Rat (*Rattus norvegicus* L.). *Majalah Obat Tradisional*, 22(3), 199–205.
- Luo, D. Q., Wu, H. H., Zhao, Y. K., Liu, J. H., & Wang, F. 2016. Original Research: Different imiquimod creams resulting in differential effects for imiquimod-induced psoriatic mouse models. *Experimental Biology and Medicine*, 241(16), 1733–1738.

- Madonna, V., Tanjung, C., & Roesyanto, I. D. 2015. Kadar Sitokin Interleukin-17 Dalam Serum Pasien Psoriasis Dan Hubungannya. *Media Dermato-Venereologica Indonesiana*, 42(17), 61–64.
- Maheswari, U., Sridevi Sangeetha, K. S., Umamaheswari, S., Uma, C., Reddy, M., & Kalkura, S. N. 2016. Flavonoids: Therapeutic Potential of Natural Pharmacological Agents. *International Journal of Pharmaceutical Sciences and Research*, 7(10), 3924–3930.
- Menting, S. P., Dekker, P. M., Limpens, J., Hooft, L., & Spuls, P. I. 2016. Methotrexate dosing regimen for plaque-type psoriasis: A systematic review of the use of test-dose, start-dose, dosing scheme, dose adjustments, maximum dose and folic acid supplementation. *Acta Dermato-Venereologica*, 96(1), 23–28.
- Morizane, S., Yamasaki, K., Mühleisen, B., Kotol, P. F., Murakami, M., Aoyama, Y., *et al.* 2012. Cathelicidin antimicrobial peptide LL-37 in psoriasis enables keratinocyte reactivity against TLR9 ligands. *Journal of Investigative Dermatology*, 132(1), 135–143.
- Murali, K. T., Rajender, V., & E. Manoj, K. 2013. In Vitro Determination Of Antioxidant Activity Of *Physalis Angulata* Linn. *International Journal Of Pharma And Bio Sciences*, 4(3), 541–549.
- Na Takuathung, M., Wongnoppavich, A., Panthong, A., Khonsung, P., Chiranthanut, N., Soonthornchareonnon, N., & Sireeratawong, S. 2018. Antipsoriatic Effects of Wannachawee Recipe on Imiquimod-Induced Psoriasis-Like Dermatitis in BALB/c Mice. *Evidence-Based Complementary and Alternative Medicine*, 2018(2), 1–13.
- Nast, A., Boehncke, W. H., Mrowietz, U., Ockenfels, H. M., Philipp, S., Reich, K., *et al.* 2012. S3 - Guidelines on the treatment of psoriasis vulgaris (English version). Update. *JDDG - Journal of the German Society of Dermatology*, 10(2), S1–S95.
- Nurfiana, G., & Sari, F. 2018. Aktivitas Antioksidan Ekstrak Dan Fraksi Herba Ciplukan (*Physalis Angulata*) Terhadap Dpph (1,1-Difenil-2-Pikrilhidrazil). *Prosiding Seminar Nasional Unimus*, 1, 98–103.
- Ogawa, E., Sato, Y., Minagawa, A., & Okuyama, R. 2017. Pathogenesis of Psoriasis and Development of Treatment. *The Journal of Dermatology*, 45(3), 264–272.
- Pathirana, D., Ormerod, A. D., Saiag, P., Smith, C., Spuls, P. I., Nast, A., *et al.* 2009. European S3-guidelines on the systemic treatment of psoriasis vulgaris. *Journal of the European Academy of Dermatology and Venereology*, 23(2), 1–70.
- Petronic-Rosic, V., & Basko-Plluska, J. 2012. Psoriasis: epidemiology, natural history, and differential diagnosis. *Psoriasis: Targets and Therapy*, 2012(2), 67–76.
- Pinto, N. B., Morais, T. C., Carvalho, K. M. B., Silva, C. R., Andrade, G. M.,

- Brito, G. A. C., *et al.* 2010. Topical anti-inflammatory potential of Physalin E from *Physalis angulata* on experimental dermatitis in mice. *Phytomedicine*, 17(10), 740–743.
- Polese, B., Zhang, H., Thurairajah, B., & King, I. L. 2020. Innate Lymphocytes in Psoriasis. *Frontiers in Immunology*, 11, 1–13.
- Pratiwi, K.D., & Damayanti. 2018. Profil Psoriasis Vulgaris di RSUD Dr. Soetomo Surabaya : Studi Retropektif. *Berkala Ilmu Kesehatan Kulit dan Kelamin – Periodical of Dermatology and Venereology*, 30(3), 248 – 254.
- Puruhito, B. 2017. Korelasi Antara Kadar IFN- γ Serum dengan Skor PASI pada Psoriasis. *Media Medika Muda*, 2(1), 63–68.
- Putri, Filu M. S. 2018. Urgensi Etika Medis dalam Penanganan Mencit pada Penelitian Farmakologi. *Jurnal Kesehatan Madani Medika*, 9(2), 51–61.
- Rendon, A., & Schäkel, K. 2019. Psoriasis pathogenesis and treatment. *International Journal of Molecular Sciences*, 20(6), 1–28.
- Shah, P., & Bora, K. S. 2019. Phytochemical and Therapeutic Potential of *Physalis* species : a Review. *IOSR Journal Of Pharmacy And Biological Sciences*, 14(4), 34–51.
- Smith, C. H. & Barker, J. N. W. N. 2006. Psoriasis and its management. *British Medical Journal*, 333(7564), 380–384.
- Soares, M. B. P., Brustolim, D., Santos, L. A., Bellintani, M. C., Paiva, F. P., Ribeiro, Y. M., *et al.* 2006. Physalins B, F and G, seco-steroids purified from *Physalis angulata* L., inhibit lymphocyte function and allogeneic transplant rejection. *International Immunopharmacology*, 6(3), 408–414.
- Susanti, R., Mateus, S. A., Henry, S. A., & Dwi, S. 2020. Gambaran Kualitas Hidup Penderita Psoriasis di Komunitas Psobat Jawa Tengah. *Jurnal Kesehatan Masyarakat (e-Journal) FKM UNDIP*, 8(3), 347–351.
- Suwarsa, O., & Sutedja, E. 2015. Tingkat Pengetahuan Penyakit Psoriasis Vulgaris Pada Masyarakat Desa Cileles, Kecamatan Jatinangor Kabupaten Sumedang. *Departemen Dermatologi Dan Venereologi, Fakultas Kedokteran Universitas Padjadjaran*, 585–591.
- Teraki, Y., Miyake, A., Takebayashi, R., & Shiohara, T. 2004. Homing receptor and chemokine receptor on intraepidermal T cells in psoriasis vulgaris. *Clinical and Experimental Dermatology*, 29(6), 658–663.
- Thamrin, H. Y. 2017. *Hematologi III*. Bahan Ajar. Kendali : D3 Analisis Kesehatan.
- van der Fits, L., Mourits, S., Voerman, J. S. A., Kant, M., Boon, L., Laman, J. D., *et al.* 2009. Imiquimod-Induced Psoriasis-Like Skin Inflammation in Mice Is Mediated via the IL-23/IL-17 Axis. *The Journal of Immunology*, 182(9), 5836–5845.

- Vertebrate Animal Research. 2020. Anesthesia Guideline. <https://animal.research.uiowa.edu/iacuc-guidelines-anesthesia>. Diakses pada 20 Juli 2020.
- Vinter, H., Iversen, L., Steiniche, T., Kragballe, K., Johansen, C., & Vinter, H. 2014. Aldara-induced skin inflammation - studies of psoriasis patients. *British Journal of Dermatology*, 172(2), 345–353.
- Weedon, D. 2009. *Weedon's Skin Pathology 3rd edition*. London : Churchill Livingstone Elsevier.
- Weigle, N. & McBane, S. 2013. Psoriasis. *American Family Physician*, 87(2013) : 626–633.
- Widaty, S, H. Soebono., H. Nilasari., M. Y. Listiawan., A. S. Siswati., D. Triwahyudi., *et al.* 2017. *Panduan Praktik Klinis bagi Dokter Spesialis Kulit dan Kelamin di Indonesia*. Jakarta: Perhimpunan Dokter Spesialis Kulit dan Kelamin Indonesia.
- World Health Organization (WHO). 2016. *Global Report on Psoriasis*. WHO Library Cataloguing-in-Publication Data. Switzerland.
- Wu, D. hong, Zhang, M. miao, Li, N., Li, X., Cai, Q. wei, Yu, W. lin, *et al.* 2019. PSORI-CM02 alleviates IMQ-induced mouse dermatitis via differentially regulating pro- and anti-inflammatory cytokines targeting of Th2 specific transcript factor GATA3. *Biomedicine and Pharmacotherapy*, 110(2018), 265–274.
- Yang, Y., Yi, L., Wang, Q., Xie, B., Sha, C., & Dong, Y. 2018. Physalin B Suppresses Inflammatory Response to Lipopolysaccharide in RAW264.7 Cells by Inhibiting NF- B Signaling. *Journal of Chemistry*, 2018, 1–6.
- Zangeneh, F. Z., & Shooshtary, F. S. 2013. Psoriasis — Types, Causes and Medication. *Intechopen*, 1, 3–38.
- Zhang, H., Samadi, A. K., Cohen, M. S., & Timmermann, B. N. 2012. Antiproliferative withanolides from the solanaceae: A structure-activity study. *Pure and Applied Chemistry*, 84(6), 1353–1367.
- Zheng, Y., Danilenko, D. M., Valdez, P., Kasman, I., Eastham-Anderson, J., Wu, J., & Ouyang, W. 2007. Interleukin-22, a TH17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. *Nature*, 445(7128), 648–651.
- Zill, J. M., Dirmaier, J., Augustin, M., Dwinger, S., Christalle, E., Härter, M., & Mrowietz, U. 2018. Psychosocial distress of patients with psoriasis: Protocol for an assessment of care needs and the development of a supportive intervention. *The Journal of Medical Internet Research-Research Protocols*, 7(2), 1–9.
- Zong, J., Cheng, J., Fu, Y., Song, J., Pan, W., Yang, L., *et al.* 2020. Serum Metabolomic Profiling Reveals the Amelioration Effect of Methotrexate on Imiquimod-Induced Psoriasis in Mouse. *Frontiers in Pharmacology*, 11, 1–11.

Zychlinsky Scharff, A., Rousseau, M., Lacerda Mariano, L., Canton, T., Consiglio, C. R., Albert, M. L., *et al.* 2019. Sex differences in IL-17 contribute to chronicity in male versus female urinary tract infection. *Journal of Clinical Investigation Insight*, 5(13), 1–19.

